Trevi Therapeutics Q2 EPS beats estimates

Trevi Therapeutics

07/08/2025 21:46

Overview

Trevi Q2 adjusted EPS beats analyst expectations, net loss narrows to $12.3 mln

Co closed $115 mln underwritten offering, cash runway expected into 2029

Outlook

Trevi expects cash runway into 2029

Company plans Phase 3 Haduvio trial in H1 2026

Trevi to request FDA End-of-Phase 2 meeting in Q4 2025

Result Drivers

PHASE 2B CORAL TRIAL - Positive topline results for Haduvio in chronic cough with IPF, achieving significant reductions in cough frequency

CASH RUNWAY - $115 mln offering completed, extending cash runway into 2029

R&D EXPENSES - Decrease in R&D expenses due to lower clinical development costs in Phase 2a and 2b trials

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
Beat
-$0.09
-$0.1 (10 Analysts)
Q2 Net Income
-$12.30 mln
Q2 Income from Operations
Miss
-$13.72 mln
-$13.30 mln (10 Analysts)
Q2 Operating Expenses
$13.72 mln
Q2 Pretax Profit
-$12.32 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Trevi Therapeutics Inc is $22.00, about 67% above its August 6 closing price of $7.27

Press Release: ID:nPn4CgKQNa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)